首页> The Lancet. Infectious diseases> Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial.

Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kirsten E,Lyke

第一单位： Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: klyke@som.umaryland.edu.

作者： Kirsten E,Lyke ^[1] ; Andrea A,Berry ^[2] ; Matthew B,Laurens ^[2] ; Jennifer,Winkler ^[2] ; Sudhaunshu,Joshi ^[2] ; Abra Rachida,Koudjra ^[2] ; Lauryn,Butler ^[2] ; Peter F,Billingsley ^[3] ; Tales,Pascini ^[4] ; Asha,Patil ^[4] ; B Kim Lee,Sim ^[4] ; Grace,Fitzgerald ^[5] ; Julie,Riegel ^[5] ; Kayla,Andrews ^[5] ; Micha,Levi ^[5] ; Aparna B,Anderson ^[5] ; Charles D,Wells ^[5] ; Hong,Liu ^[5] ; James,Huleatt ^[5] ; R Scott,Miller ^[5]

作者单位： Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: klyke@som.umaryland.edu. ^[1] Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA. ^[2] Sanaria, Rockville, MD, USA; The Vital Narrative, Frederick, MD, USA. ^[3] Sanaria, Rockville, MD, USA. ^[4] Gates Medical Research Institute, Cambridge, MA, USA. ^[5]